Stock CMPX COMPASS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Compass Therapeutics, Inc. OTC Markets

Equities

CMPX

US20454B1044

Delayed OTC Markets
Other stock markets
 19:59:57 03/11/2021 GMT 		5-day change 1st Jan Change
3.55 USD -10.80% Intraday chart for Compass Therapeutics, Inc. +32.67% -.--%
05-28 Compass Therapeutics Appoints Thomas Schuetz as CEO MT
05-28 Compass Therapeutics, Inc. Announces CEO Changes CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024
CI
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Top Premarket Gainers
MT
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
CI
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
MT
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer
CI
Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 Study of Ctx-009 in Biliary Tract Cancer at the 2023 ASCO GI Cancers Symposium
CI
Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 Therapy
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Compass Therapeutics Working With Merck to Conduct Clinical Trial of CTX-471
MT
Compass Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA (Pembrolizumab)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMPX Stock
  4. CMPX Stock
  5. News Compass Therapeutics, Inc.
  6. Highlights